



Novel Antiprotozoal Drug Formulations and Treatments

Guest Editors:

Dr. Željko Petrovski

LAQV-REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa, 2829-516 Caparica, Portugal

Dr. Luis Cobra Branco

Departamento de Química, LAQV-REQUIMTE, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2825-149 Caparica, Portugal

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Dear Colleagues,

Protozoan parasites such as *Plasmodium* spp., *Trypanosoma* spp. are responsible for diseases that cause significant mortality, morbidity and economic burden, predominantly in developing countries. There are currently no effective vaccines against these diseases. Therefore, the treatment of malaria, human African trypanosomiasis (HAT), Chagas disease and leishmaniasis relies heavily on new drug discovery and the development of novel effective, safe and inexpensive antiprotozoal treatments. This Special Issue aims to gather review papers and original research articles dealing with the potential antiprotozoal activities of novel drug candidates, modes of action and drug formulations. We welcome contributions on the following topics: synthesis and evaluation of the antiprotozoal activity of new compounds; the preparation and evaluation of drug formulations; combination therapy of antiprotozoal drugs and other substances; in vitro and in vivo evaluation; mechanisms of action; and drug resistance.

Keywords: antiprotozoal activity and treatment; drug formulations; mechanism of action and resistance to antiprotozoal drugs; malaria





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi